Translational research in oncology: the need of additional in vitro preclinical testing methods for new drugs

Area of Science:

• Oncology
• Drug Discovery
• Cancer Metastasis Research

Background:

• Cancer is a leading cause of death, with metastasis driving mortality.
• Current drug development relies on in vitro models lacking predictive power for anti-metastatic therapies.
• Existing screening methods focus on cytotoxicity or cell growth inhibition, neglecting metastasis.

Purpose of the Study:

• To review current in vitro models in oncology.
• To introduce a new rationale for preclinical development of anti-metastatic agents.
• To address the limitations of existing models in assessing anti-metastatic drug activity.

Main Methods:

• Literature review of current in vitro oncology models.
• Analysis of limitations in assessing anti-metastatic drug efficacy.
• Proposal of a new framework for preclinical anti-metastatic drug development.

Main Results:

• Current in vitro models are insufficient for evaluating anti-metastatic drug potential.
• There is a critical need for predictive models to guide the development of anti-cancer drugs targeting metastasis.
• Existing models do not adequately assess the key aspect of cancer cell invasion and metastasis.

Conclusions:

• A paradigm shift in preclinical oncology models is necessary.
• Developing specific anti-metastatic agents requires novel in vitro and in vivo assessment strategies.
• The proposed rationale aims to improve the preclinical evaluation of drugs targeting cancer metastasis.